EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.
about
One-Carbon Metabolism in Prostate Cancer: The Role of Androgen SignalingCellular and molecular biology of small cell lung cancer: an overviewLongitudinal Study of DNA Methylation of Inflammatory Genes and Cancer RiskFunctional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery.Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.Targeting of cancer stem cells by inhibitors of DNA and histone methylation.Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase.Mutations and deletions of PRC2 in prostate cancer.Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence.3-Deazaneplanocin A and neplanocin A analogues and their effects on apoptotic cell death.Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatmentHuman Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis.IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors.Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
P2860
Q26740548-3BAE0846-2D1E-4ADE-8956-577EBC004374Q26767029-9A15D00D-5EA8-48D8-AD62-70E13FE5C5F4Q28390230-A7B545C1-5F65-48ED-907A-083CB45C28E7Q28546856-25B884AC-A84E-42E6-B656-0FD373421D72Q34797680-D8F56679-A2CE-4F49-BDDA-F7B7B6E6B99BQ35942323-313366D7-144F-407E-8318-D0BCE7024786Q36042596-9C8B54AC-4FBD-4229-AC03-5BEA97542F2EQ36811784-C39C64EA-8E79-4D1B-8505-4569D59D0DC2Q38362686-B2C1800E-6FF0-4E6D-B6C4-9417BF6B8794Q38500320-797FC1FB-C26B-4C37-92CE-C8B63B6B24ABQ38594002-32050FB2-1B47-4CA6-B833-6DB55A3CE42EQ38698037-C11E111B-8281-4234-BDA7-C214EC617AF7Q38783694-1A6D8AC2-753F-47E6-B793-A71F5601CEA9Q38825651-40E8BF91-F085-444C-BB16-970B4D4BA38BQ38947403-3C984161-7D3C-465D-8F09-46853EC04C73Q40014635-6E66957F-390C-4CDA-8B7B-DA2229D2C8C0Q40422515-C03E924D-E487-44D8-9C89-82D4B726B9F7Q47273046-E98C560E-5FC0-48AA-9C00-7B61F4C6098AQ47337796-C4039F81-5C6C-4F9F-AEC8-36FA3B6E4738Q52342542-4B64DA01-1857-4E87-B621-E6E612C3E3C9
P2860
EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
EZH2-mediated inactivation of ...... in MYC-driven prostate cancer.
@en
type
label
EZH2-mediated inactivation of ...... in MYC-driven prostate cancer.
@en
prefLabel
EZH2-mediated inactivation of ...... in MYC-driven prostate cancer.
@en
P2093
P1433
P1476
EZH2-mediated inactivation of ...... in MYC-driven prostate cancer
@en
P2093
Puay Leng Lee
Shuet Theng Lee
Yoon Pin Lim
Zhen Ning Wee
P304
P356
10.1016/J.CELREP.2014.05.045
P50
P577
2014-06-19T00:00:00Z